Cabozantinib is a targeted small-molecule therapy used in the treatment of several advanced cancers. It is known for its broad activity against multiple signaling pathways that contribute to tumor growth, angiogenesis, and metastatic spread, making it an important option in modern oncology.

At the molecular level, Cabozantinib functions as a multi-tyrosine kinase inhibitor. It targets receptors such as MET, VEGFR, AXL, RET, and others that are involved in cancer cell proliferation and tumor blood-vessel formation. By inhibiting these pathways simultaneously, Cabozantinib helps slow disease progression and reduce tumor aggressiveness.

Because Cabozantinib is used in long-term cancer management and across multiple indications, molecular stability, purity, and formulation consistency are critical. These properties ensure predictable pharmacological behavior, sustained efficacy, and adherence to global regulatory standards. Cabozantinib has become a key molecule in the treatment of advanced and treatment-resistant cancers.

Prescribing Information

Prescribing information provides official guidance on approved indications, dosing regimens, administration instructions, contraindications, and safety monitoring.

Clinical Trial Details

Cabozantinib has been evaluated in multiple pivotal clinical trials supporting its use in different cancer types. Key studies include METEOR, CABOSUN, and CELESTIAL, which demonstrated significant clinical benefit in renal cell carcinoma, hepatocellular carcinoma, and other advanced malignancies.

FDA Approval Status

Cabozantinib is approved by the U.S. Food and Drug Administration for multiple oncology indications, including advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. It is marketed under the brand names Cabometyx® and Cometriq® by Exelixis.